Drug Interactions between nivolumab and rozanolixizumab
This report displays the potential drug interactions for the following 2 drugs:
- nivolumab
- rozanolixizumab
Interactions between your drugs
nivolumab rozanolixizumab
Applies to: nivolumab and rozanolixizumab
MONITOR: Concomitant use of a human neonatal Fc receptor (FcRn) blocker like efgartigimod alfa or rozanolixizumab may decrease the plasma concentrations and therapeutic effects of medications that bind to the FcRn such as immune globulins, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass (e.g., abatacept, aflibercept, asfotase alfa, belatacept, dulaglutide, etanercept, luspatercept, rilonacept, romiplostim, and some recombinant coagulation factors). FcRn blockers target the FcRn, a widely expressed receptor that plays a critical role in recycling and maintaining homeostatic levels of circulating IgG and other antibodies by preventing their cellular degradation.
MANAGEMENT: The potential for reduced effectiveness of medications that bind to the human neonatal Fc receptor should be considered during concomitant treatment with FcRn blockers. When long-term use of such medications is required, consider discontinuing the FcRn blocker and using alternative therapies.
References
- (2022) "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc.
- (2023) "Product Information. Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase)." argenx US Inc.
- (2023) "Product Information. Rystiggo (rozanolixizumab)." UCB Pharma Inc
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.